Market open
Arcus Biosciences/$RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
$RCUS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
627
Website
RCUS Metrics
BasicAdvanced
$861M
-
-$3.14
0.83
-
Price and volume
Market cap
$861M
Beta
0.83
52-week high
$18.75
52-week low
$6.50
Average daily volume
1.2M
Financial strength
Current ratio
4.496
Quick ratio
4.438
Long term debt to equity
30.309
Total debt to equity
32.784
Interest coverage (TTM)
-77.50%
Management effectiveness
Return on assets (TTM)
-17.26%
Return on equity (TTM)
-59.77%
Valuation
Price to revenue (TTM)
2.839
Price to book
1.55
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-4.162
Growth
Revenue change (TTM)
120.51%
Earnings per share change (TTM)
-24.29%
3-year revenue growth (CAGR)
-12.34%
3-year earnings per share growth (CAGR)
64.16%
What the Analysts think about RCUS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
RCUS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RCUS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RCUS News
AllArticlesVideos
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire·6 days ago
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
Business Wire·1 week ago
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $861M as of April 30, 2025.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of April 30, 2025.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of April 30, 2025.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.